Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Transiliac undecalcified bone biopsy specimens were taken after tetracycline double labeling from 14 patients with radiologic evidence of osteosclerotic metastases from prostatic carcinoma. The histomorphometric analysis showed an increased trabecular bone volume in all patients, and in seven morphologic and dynamic evidence of osteomalacia (Group 1). The seven other patients demonstrated an extension of apposition surfaces without evidence of osteomalacia (Group 2). Group 1 was different from Group 2 in terms of a greater increase in serum alkaline phosphatase and a lower urinary calcium. In four Group 1 patients, a second bone sample taken after two to six months of treatment with vitamin D and calcium provided evidence of improving osteomalacia. The high incidence of osteomalacia in osteosclerotic metastases of prostatic origin appears to be the result of the increase in bone formation induced by prostatic cells, and the unability to satisfy the high calcium demand for new bone.
 ...
PMID:Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. 668 95

A patient with carcinoma of the prostate, extensive bony metastases, and osteomalacia is reported. The diagnosis of osteomalacia was suspected because of generalized weakness and bone pains, hypocalcemia, hypophosphatemia, and raised alkaline phosphatase. It was documented by low 1,25-dihydroxyvitamin D level. Furthermore, it was confirmed by improvement in patient's symptomatology and normalization of serum calcium and phosphorus after treatment with 1,25-dihydroxyvitamin D3 (Rocaltrol).
 ...
PMID:Osteomalacia associated with prostatic cancer and osteoblastic metastases. 668 13

Assays of serum immunoreactive parathyroid hormone are clinically useful in the differential diagnosis of hypercalcaemic states and in the assessment of the severity of parathyroid bone disease in uraemic patients. Serum immunoreactive calcitonin measurements are essential in the investigation of individuals who might be suffering from medullary carcinoma and may be used in the detection of metastases. Serum 25-hydroxyvitamin D assays should be performed in patients receiving pharmacological doses of vitamin D to monitor patient compliance and to prevent the occurrence of vitamin D intoxication. Low values in patients with renal failure and in patients with malabsorption are highly suggestive of the presence of osteomalacia. The measurement of serum levels of dihydroxylated vitamin D metabolites is currently of doubtful relevance though such measurements may become useful in monitoring patients receiving these compounds therapeutically.
 ...
PMID:The measurement of calcium-regulating hormones in clinical medicine. 720 1

In connection with two observations histologically proved on a metastasic territory of osteomalacia appeared during osteocondensing metastases of prostatic origin, the authors underline the responsibility of sudden increase of osteoformation in the hypocalcemia genesis and put the emphasis on the transitory aggravating function of the given high doses of estrogen within negative calcium balance. A D vitamin deficiency, frequent among old patients, could increase osseous manifestation of calcium supply insufficiency responsible of an authentic osteomalacia. This deficiency is not secondary to a phosphorus diabetes and is amended by an important calciu addition and by the administration of D vitamin metabolites as proved by repeated osseous biopsy with dynamic and histomorphometric studies.
 ...
PMID:[Vitamin-sensitive osteomalacia in condensing bone metastases of prostatic origin. Apropos of 2 cases]. 725 62

Hypophosphatemic osteomalacia that remits after resection of a coexisting tumor has been described in 35 patients. Because the associated neoplasms have been of mesenchymal origin, it has been inferred that this tumor-induced osteomalacia syndrome is uniquely related to tumours of this derivation. However, in the present investigation we studied subjects with coincident hypophosphatemia and prostatic carcinoma to ascertain whether this endodermal malignancy causes the tumor-induced osteomalacia syndrome. The hypophosphatemic patients had renal phosphate wasting, gastrointestinal malabsorption of calcium and phosphate, and negative phosphate balance. Moreover, bone biopsies showed histomorphologic changes indicative of osteomalacia. Although widespread metastases precluded establishing the diagnosis of tumor-induced osteomalacia by resection of the tumor, a series of studied excluded alternate causes for the osteomalacia. Further, affected subjects had a normal serum concentration of 25-hydroxyvitamin D, 28.0 +/- 8.3 ng/mL, and serum 1,25-dihydroxyvitamin D levels were low, 15.0 +/- 1.0 pg/mL, characteristic of the tumor-induced osteomalacia syndrome. Thus, prostatic carcinoma, although an endodermal malignancy, may cause the tumor-induced osteomalacia syndrome.
 ...
PMID:Hypophosphatemic osteomalacia: association with prostatic carcinoma. 740 80

Assays of serum immunoreactive parathyroid hormone are clinically useful in the differential diagnosis of hypercalcaemic states and in the assessment of the severity of parathyroid bone disease in uraemic patients. Serum immunoreactive calcitonin measurements are essential in the investigation of individuals who might be suffering from medullary carcinoma, and such measurements may be used in the detection of metastases. Serum 25-hydroxyvitamin D assays are useful in patients receiving pharmacological doses of vitamin D, to monitor patient compliance and to prevent the occurrence of vitamin D intoxication. Low values in patients with renal failure and in patients with malabsorption and highly suggestive of the presence of osteomalacia. The measurement of serum levels of dihydroxylated vitamin D metabolites is currently of doubtful clinical relevance, though such measurements may become useful in monitoring patients receiving these compounds therapeutically.
 ...
PMID:Testing for disorders of calcium metabolism. 746 49

Quantitative whole-body bone scans were performed on 277 patients with bone metastases, diseases of the joint and systemic bone diseases in order to evaluate the clinical significance of quantitative and kinetic data in bone imaging. Metastases and other focal bone diseases are recognizable and quantifiable by the method; however, sensitivity and specificity of bone imaging are not enhanced. In metabolic bone diseases, with the exception of osteoporosis, kinetic data facilitate the analysis of bone scans. Typical signs of osteomalacia, hyperparathyroidism and renal osteodystrophy--increased retention of the activity in the skeleton and increased bone/soft tissue ratios as well as a generally changed distribution of radioactivity--are only recognizable by quantitative imaging.
 ...
PMID:[Quantitative whole-body bone scintigraphy. III. Clinical significance for the diagnosis of bone metastases, systemic bone diseases and diseases of the joint (author's transl)]. 746 30

Clodronate relieves bone pain in patients with skeletal metastases. Since the pain relieving mechanism of clodronate may be associated with the antiosteoclastic activity, we have investigated whether the drug has simultaneous actions on bone resorption and pain. Although osteosclerotic metastases are characteristic of prostate carcinoma, bone resorption is also accelerated. The resorbing process can be investigated using a specific immunoassay for ICTP (cross-linked carboxyterminal telopeptide region of type I collagen) which allows the measurement of the degradation of type I collagen in serum samples. We have also determined serum concentration of PICP (carboxyterminal propeptide of type I procollagen) which reflects the synthesis of type I collagen (osteoid). Patients who have relapsed after first-line hormonal therapy, were randomised to receive estramustine phosphate (E) with or without clodronate (C) (E + C, n = 50; E, n = 49). The dose of E was 560 mg and that of C 3.2 g for the first month, thereafter 1.6 g. We saw elevated ICTP and PICP levels in the majority of the patients. A transient decrease in ICTP values occurred simultaneously with pain relief. The changes were more accentuated in the E + C than in the E group but the difference was not significant. In each group serum phosphate concentration decreased markedly (P = 0.001) whereas the activity of alkaline phosphatase remained increased, both indicating a development of osteomalacia during E therapy. The short-term antiosteoclastic effect of C may be explained by the dose reduction, hyperosteoidosis and osteomalacia which inhibit the binding of C on the crystal surfaces and by the late phase of disease.
 ...
PMID:Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. 768 80

Though vertebral fractures were required to make the diagnosis of osteoporosis prior to the advent of methods for accurate bone measurement, osteopenia is readily defined by a decrease of bone mineral density by 2 to 2.5 SD from the peak bone density. After excluding other metabolic bone diseases such as primary hyperparathyroidism, osteomalacia, renal osteodystrophy, multiple myeloma and tumor metastases by means of X-ray studies and biochemical studies on serum and urine, by far the largest proportion of patients with osteopenia are usually found to have osteoporosis. Primary osteoporosis is found in males and females after middle age, and secondary osteoporosis at any age with definite causes such as corticosteroid excess, immobilization, rheumatoid arthritis or vitamin C deficiency. Estrogen withdrawal in young women is classified as secondary osteoporosis, but postmenopausal osteoporosis with similar cause is usually classified into primary osteoporosis, creating a confusion. Rapid bone loss occurring only during a few years after menopause should be clearly distinguished from the life-long process of bone loss common to males and females and should not be classified as a "type" of osteoporosis.
 ...
PMID:[Osteoporosis--concept, classification and epidemiology]. 796 67

We studied the histological indices of skeletal turnover in 40 patients with carcinoma of the prostate and skeletal metastases in order to determine the prevalence of osteomalacia. In 20 patients biopsied through uninvolved bone, the histological indices of bone turnover were normal. In particular, osteoid seam width and bone formation rates were consistently normal, indicating the absence of osteomalacia. In biopsies from tumour-laden bone, hyperosteoidosis was present, usually associated with increased amounts of woven collagen and consistently associated with high rates of bone formation and mineralisation. It was concluded that hyperosteoidosis in prostatic cancer is rarely due to osteomalacia.
 ...
PMID:Distinction between focally accelerated bone formation and osteomalacia in carcinoma of prostate metastasised to bone. 814 87


<< Previous 1 2 3 4 5 Next >>